LAB Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Standard Biotools Inc. had $85.3M of revenue in fiscal 2025, down 6.2% on the year before. Over five years, revenue changed β9.2% a year on average.
Last close Β· Oct 23, 2026
$0.61
4.7%Hi! I read Standard Biotools Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β6.2%
No. Sales fell 6.2% last year.
Does it make a profit?
β87.8%
No. It lost money last year.
Does profit turn into cash?
β96.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
2.8x
One share costs 2.8 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Standard Biotools Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 3, 2026
Tuesday Β· in 8 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 5, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 8, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 4, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 11, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 6, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Oct 30, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Standard Biotools Inc. had $85.3M of revenue in fiscal 2025, down 6.2% on the year before. Over five years, revenue changed β9.2% a year on average. Its operating margin was β129.2%, up 10.9Β pts: of every 100 in sales, about β129 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Standard Biotools Inc. lost $74.9M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$82.6M in fiscal 2025, β96.9% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Standard Biotools Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 8.0%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Standard Biotools Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $28.5M | $166M | $115M | $293M | $188M |
| Debt incl. finance leases | β | $64.9M | $63.5M | $0.3M | β |
| Debt / equity | β | β | β | 0.0x | β |
| Interest coverage | β17.6x | β26.8x | β16.8x | β | β |
| Current ratio | 1.5x | 4.8x | 1.4x | 5.7x | 4.2x |
| Quick ratio | 1.0x | 4.3x | 1.3x | 5.4x | 4.0x |
| Total assets | $275M | $390M | $323M | $612M | $568M |
| Total liabilities | $181M | $161M | $160M | $141M | $143M |
| Shareholders' equity | $94.6M | β$81.5M | β$148M | $472M | $424M |
| Net debt (β = net cash) | β | β$101M | β$51.4M | β$293M | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Standard Biotools Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 5 / 8 | 3 / 8 | 2 / 7 | 2 / 7 | 2 / 7 | 4 / 9 | 4 / 9 | 4 / 8 |
| Accruals ratio | β12.0% | β12.3% | β11.4% | β10.4% | β12.8% | β5.1% | β30.3% | β8.8% | 1.0% | β0.1% |
| Altman Z'' | β4.62 | β5.51 | β4.80 | β5.98 | β5.78 | β9.28 | β7.49 | β11.67 | β0.87 | β1.44 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $104M | $102M | $113M | $117M | $138M | $131M | $97.9M | $106M | $91.0M | $85.3M |
| Gross profit | $58.4M | $52.0M | $61.6M | $64.3M | β | β | $37.1M | $50.5M | $44.9M | $42.5M |
| Research and development | $38.4M | $30.8M | $30.0M | $31.6M | $36.5M | $37.9M | $37.4M | $25.9M | $28.8M | $26.0M |
| Operating income | β$73.2M | β$58.4M | β$48.2M | β$51.8M | β$51.0M | β$67.5M | β$116M | β$76.6M | β$127M | β$110M |
| Interest expense | $5.8M | $5.8M | $13.9M | $4.3M | $3.6M | $3.8M | $4.3M | $4.6M | β | β |
| Pretax income | β$80.2M | β$63.8M | β$61.4M | β$66.7M | β$54.1M | β$63.7M | β$193M | β$74.2M | β$90.4M | β$96.7M |
| Income tax | β$4.2M | β$3.3M | β$2.4M | β$1.9M | β$1.1M | β$4.4M | β$2.8M | $0.5M | $0.5M | β$37.9M |
| Net income | β$76.0M | β$60.5M | β$59.0M | β$64.8M | β$53.0M | β$59.2M | β$190M | β$74.7M | β$139M | β$74.9M |
| Net income to common | β | β | β | β | β | β | β$190M | β$74.7M | β$185M | β$74.9M |
| Diluted EPS | β$2.62 | β$1.84 | β$1.49 | β$0.97 | β$0.74 | β$0.78 | β$2.43 | β$0.94 | β$0.52 | β$0.20 |
| Diluted shares | 0.03B | 0.03B | 0.04B | 0.07B | 0.07B | 0.08B | 0.08B | 0.08B | 0.35B | 0.38B |
| Cash flow | ||||||||||
| Cash from operations | β$39.1M | β$24.1M | β$25.2M | β$35.2M | β$15.4M | β$44.1M | β$89.4M | β$43.3M | β$143M | β$74.3M |
| Capital expenditure | $5.1M | $1.6M | $0.4M | $2.5M | $12.7M | $13.3M | $3.8M | $2.8M | $8.4M | $8.3M |
| Free cash flow | β$44.2M | β$25.7M | β$25.6M | β$37.7M | β$28.1M | β$57.3M | β$93.2M | β$46.1M | β$152M | β$82.6M |
| Depreciation and amortization | $6.7M | $7.4M | $5.4M | $4.6M | $4.0M | $3.2M | $12.5M | $12.7M | $12.3M | $9.3M |
| Stock-based compensation | $13.9M | $9.1M | $11.0M | $11.4M | $14.5M | $16.1M | $14.9M | $13.1M | $31.7M | $29.6M |
| Acquisitions | $0.0M | β | $0.0M | $0.0M | $5.2M | $0.0M | β | $0.0M | $1.4M | $0.0M |
| Share buybacks | β | β | β | β | β | $0.0M | $0.6M | $5.4M | $40.5M | $0.0M |
| Dividends and buybacks | β | β | β | β | β | $0.0M | $0.6M | $5.4M | $40.5M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $59.4M | $63.1M | $95.4M | $58.6M | $68.5M | $28.5M | $166M | $115M | $293M | $188M |
| Total debt | β | $195M | β | β | β | β | $64.9M | $63.5M | $0.3M | β |
| Current assets | $96.7M | $94.8M | $127M | $96.1M | $118M | $72.1M | $209M | $158M | $376M | $454M |
| Current liabilities | $29.5M | $33.5M | $37.6M | $32.8M | $54.2M | $49.6M | $43.4M | $109M | $65.9M | $108M |
| Inventory | $20.1M | $15.1M | $13.0M | $13.9M | $19.7M | $20.8M | $21.5M | $20.5M | $20.7M | $20.0M |
| Property and equipment, net | $16.5M | $12.3M | $8.8M | $8.1M | $17.5M | $28.0M | $25.7M | $24.2M | $22.8M | $19.3M |
| Goodwill | $104M | $104M | $104M | $104M | $107M | $106M | $106M | $106M | $111M | β |
| Intangible assets | $79.8M | $68.6M | $57.4M | $46.2M | $40.2M | $27.9M | $12.6M | $1.4M | $29.0M | β |
| Total assets | $306M | $287M | $304M | $265M | $325M | $275M | $390M | $323M | $612M | $568M |
| Total liabilities | $253M | $256M | $232M | $111M | $186M | $181M | $161M | $160M | $141M | $143M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Shareholders' equity | $53.2M | $30.9M | $72.1M | $154M | $139M | $94.6M | β$81.5M | β$148M | $472M | $424M |
| Margins | ||||||||||
| Gross margin | 55.9% | 51.0% | 54.6% | 54.8% | β | β | 37.8% | 47.4% | 49.3% | 49.9% |
| Operating margin | β70.1% | β57.3% | β42.6% | β44.2% | β36.9% | β51.7% | β118.6% | β72.0% | β140.1% | β129.2% |
| EBITDA margin | β63.6% | β50.0% | β37.9% | β40.3% | β34.0% | β49.2% | β105.9% | β60.1% | β126.6% | β118.3% |
| Net margin | β72.8% | β59.4% | β52.2% | β55.3% | β38.4% | β45.4% | β194.1% | β70.2% | β152.6% | β87.8% |
| FCF margin | β42.3% | β25.2% | β22.6% | β32.2% | β20.4% | β43.9% | β95.1% | β43.4% | β166.8% | β96.9% |
| Returns | ||||||||||
| Return on capital | β | β28.3% | β | β | β | β | β | β | β56.2% | β |
| Return on capital employed | β26.4% | β23.0% | β18.1% | β22.3% | β18.9% | β29.9% | β33.5% | β35.8% | β23.3% | β24.0% |
| Return on equity | β142.7% | β143.8% | β114.5% | β57.4% | β36.2% | β50.7% | β2,895.8% | β | β85.8% | β16.7% |
| Return on assets | β24.8% | β20.4% | β20.0% | β22.8% | β18.0% | β19.7% | β57.1% | β20.9% | β29.7% | β12.7% |
| Return on tangible equity | β | β | β | β1,961.0% | β | β | β | β | β55.8% | β17.7% |
| Growth | ||||||||||
| Revenue growth | β | β2.4% | 10.8% | 3.8% | 17.8% | β5.5% | β25.0% | 8.6% | β14.4% | β6.2% |
| Share count change | β | 13.7% | 20.2% | 68.4% | 7.9% | 5.2% | 3.3% | 1.1% | 346.2% | 8.0% |
| Financial health | ||||||||||
| Debt / equity | β | 6.3x | β | β | β | β | β | β | 0.0x | β |
| Interest coverage | β12.6x | β10.0x | β3.5x | β12.1x | β14.3x | β17.6x | β26.8x | β16.8x | β | β |
| Current ratio | 3.3x | 2.8x | 3.4x | 2.9x | 2.2x | 1.5x | 4.8x | 1.4x | 5.7x | 4.2x |
| Quick ratio | 2.6x | 2.4x | 3.0x | 2.5x | 1.8x | 1.0x | 4.3x | 1.3x | 5.4x | 4.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 4.8% | 1.5% | 0.3% | 2.2% | 9.2% | 10.2% | 3.9% | 2.7% | 9.2% | 9.7% |
| Stock comp / revenue | 13.3% | 8.9% | 9.8% | 9.7% | 10.5% | 12.3% | 15.2% | 12.3% | 34.9% | 34.7% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 5.0 | 3.0 | 2.0 | 2.0 | 2.0 | 4.0 | 4.0 | 4.0 |
| Altman Z'' | β4.6 | β5.5 | β4.8 | β6.0 | β5.8 | β9.3 | β7.5 | β11.7 | β0.9 | β1.4 |
| Accruals ratio | β12.0% | β12.3% | β11.4% | β10.4% | β12.8% | β5.1% | β30.3% | β8.8% | 1.0% | β0.1% |
Source: SEC EDGAR XBRL filings (CIK 0001162194). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
